MacroGenics reports Q1 net loss $38M; cash runway through 2025 on $270M non-dilutive funding

MACROGENICS INC

2023-Q1 EPS reported -$0.61 revenue$24,496,000

Net loss of $38.0M ($0.61 loss per share) vs. $66.4M loss year ago; revenue $24.5M (up 121% YoY).
Cash, equivalents & marketable securities $241.7M at March 31, 2023; additional $30M approval milestone from TZIELD received after Q1.
ZYNYZ (retifanlimab) approved by FDA for MCC; MacroGenics received $15M milestone, eligible for up to $650M more plus tiered royalties.
Sold TZIELD royalty interest to DRI for $100M upfront; retains 50% share above threshold and up to $430M in Sanofi milestones.
Phase 2 TAMARACK (vobra duo in mCRPC) enrollment under revised protocol to start Q2 2023; clinical update expected in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.